Krystal Biotech (KRYS) Net Income towards Common Stockholders Growth (1y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1,228.66% |
| 10 | Krystal Biotech | 9.05 Bn | 8.23 Bn | 110.03 Mn | 56.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.53% |
| Dec 31, 2025 | 12.93% |
| Sep 30, 2025 | 192.00% |
| Jun 30, 2025 | 146.50% |
| Mar 31, 2025 | 3,734.01% |
| Dec 31, 2024 | 423.62% |
| Sep 30, 2024 | -66.34% |
| Jun 30, 2024 | 146.88% |
| Mar 31, 2024 | 102.06% |
| Dec 31, 2023 | 127.12% |
| Sep 30, 2023 | 370.51% |
| Jun 30, 2023 | -18.15% |
| Mar 31, 2023 | 9.34% |
| Dec 31, 2022 | -46.99% |
| Sep 30, 2022 | -91.48% |
| Jun 30, 2022 | -71.78% |
| Mar 31, 2022 | -215.99% |
| Dec 31, 2021 | -110.02% |
| Sep 30, 2021 | -62.22% |
| Jun 30, 2021 | -139.47% |
| Mar 31, 2021 | -196.05% |
| Dec 31, 2020 | -93.82% |
| Sep 30, 2020 | -124.95% |
| Jun 30, 2020 | -27.77% |
| Mar 31, 2020 | -29.92% |
| Dec 31, 2019 | -44.47% |
| Sep 30, 2019 | -55.06% |
| Jun 30, 2019 | -134.97% |
| Mar 31, 2019 | -91.21% |
| Dec 31, 2018 | -166.19% |
| Sep 30, 2018 | 47.75% |
| Jun 30, 2018 | -199.87% |
| Mar 31, 2018 | -335.22% |
| Dec 31, 2017 | -122.17% |
| Sep 30, 2017 | -1,537.58% |